Johnson & Johnson's orthopedic sales stay flat in Q3


Johnson & Johnson saw mild sales growth in the third quarter, while orthopedic sales stayed stagnant, according to financial results posted Oct. 18.

Four things to know:

1. Worldwide orthopedic sales of $2.1 billion remained the same compared to the third quarter of 2021. U.S. sales grew 4 percent with $1.3 billion, and international sales dipped 6.9 percent.

2. Global hip sales were about the same in the third quarter, falling 0.9 percent year over year. Knee sales grew 0.4 percent.

3. The trauma and spine and sports segments saw minimal growth. Trauma sales in the third quarter of 2022 was $717 million, compared to $715 million in 2021. Spine and sports sales were $708 million in the third quarter of 2022 compared to $706 million in the same period in 2021.

4. Johnson & Johnson's total third-quarter revenue of $23.8 billion was up 1.9 percent compared to the same time last year.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers